A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study
Authors:
- 11 January 2022
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 260 (6) , 1941-1946
Abstract
Background Benzalkonium chloride (BAK), the most commonly used preservative in anti-glaucoma eye drops, inflicts damage to the ocular surface. A novel anti-glaucoma formulation that avoids the use of BAK has been developed. The aim of this study was to evaluate the cytotoxicity of this formulation and to compare it with an ophthalmic solution containing BAK. Methods Two different latanoprost eye drops were used: one ophthalmic solution (LSc) containing BAK 0.02% and one ophthalmic nanoemulsion (LNe) with a soft preservative (potassium sorbate 0.18%). Human epithelial conjunctival cells were incubated for 15, 30, and 60 min with either LSc or LNe. The cytotoxicity was determined by MTT assay. Cell death was measured by flow cytometry using annexin V–FITC and propidium iodide. Results The values of cell viability and proliferation obtained from cells exposed to LNe were between 80 and 90% relative to the control group, whereas values obtained from cells exposed to LSc were around 30% at all study times (p < 0.05 at 15 and 30 min; p < 0.01 at 60 min). The percentage of viable cells decreased significantly when cells were incubated with LSc compared with cells incubated with LNe at all the study times, while the percentage of cells in late apoptosis/necrosis increased significantly in cells exposed to LSc compared to LNe. Conclusions The new latanoprost nanoemulsion is significantly less cytotoxic on human conjunctival cells than LSc. These results suggest that the new formulation might be gentler on the eye surface than currently available BAK-preserved latanoprost solutions.Keywords
This publication has 33 references indexed in Scilit:
- Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma TreatmentsCurrent Eye Research, 2014
- How Ocular Surface Disease Impacts the Glaucoma Treatment OutcomeBioMed Research International, 2013
- Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine modelMucosal Immunology, 2012
- The Cytotoxic Effects of Preserved and Preservative-Free Prostaglandin Analogs on Human Corneal and Conjunctival EpitheliumIn Vitroand the Distribution of Benzalkonium Chloride Homologs in Ocular Surface TissuesIn VivoCurrent Eye Research, 2011
- Preservatives in eyedrops: The good, the bad and the uglyProgress in Retinal and Eye Research, 2010
- Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cellsToxicology in Vitro, 2010
- Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmologica, 2008
- In VitroEffects of Preservative-Free Tafluprost and Preserved Latanoprost, Travoprost, and Bimatoprost in a Conjunctival Epithelial Cell LineCurrent Eye Research, 2008
- In Vitro Comparison of Cytoprotective and Antioxidative Effects of Latanoprost, Travoprost, and Bimatoprost on Conjunctiva-Derived Epithelial CellsInvestigative Ophthalmology & Visual Science, 2005
- Human Lens Epithelial Cell Damage and Stimulation of Their Secretion of Chemical Mediators by Benzalkonium Chloride Rather Than Latanoprost and TimololArchives of Ophthalmology (1950), 2003